Investors who are considering buying or selling Resmed shares through their stock market portfolio or trading on the price of this stock directly on the market should first of all be interested in the elements and information that allow them to make a good analysis of its stock price. Thus, in this article dedicated to this stock, we will provide you with this information by first presenting the company Resmed and its activities and sources of income, its main competitors on the market and in its sector of activity, its recent partnerships as well as other stock market data. We will also explain how to set up a good fundamental analysis of this stock with the most impactful elements.
In view of the sector in which the Resmed group currently operates, it will be necessary to closely follow all of its innovations as well as the investments made in research and development in order to always remain at the forefront of this innovation.
It will also be necessary to follow Resmed's various competitors and their major news and results, and to take into account the evolution of the sector's market share.
We will also have to keep an eye on the international expansion of the group, which could seek to establish itself in new markets where it is not yet present through strategic operations such as takeovers or partnerships with other companies.
Finally, the Group's financial results, which are published annually and quarterly, should be closely monitored and compared with previous results, analysts' expectations and the targets set by the Group.
Now we would like to give you more information about Resmed to help you understand how it generates its profits and in which segments of the sector it is present.
The ResMed Group Inc. is a US-based medical technology company. Specifically, the group is engaged in the design, manufacture and marketing of medical devices and software for the diagnosis, treatment and management of respiratory disorders including sleep-disordered breathing.
In order to better understand the activities of the ResMed Group, they can be divided into different categories according to the share of turnover they generate and in this way:
Currently, the ResMed Group has more than six manufacturing facilities in the United States, Australia, France, China, Singapore and Malaysia. However, it still generates 60.9% of its sales in the US and employs more than 7,970 people.
Of course, it is also important to know the competition of this company in order to take into account the news of its opponents on the market. We therefore suggest that you find out who its main competitors are:
This Amsterdam-based Dutch technology company is one of the largest groups in the home appliances and lighting segment in the world, with more than 114,000 employees in about 100 countries. However, the group is organized into three business units, including Philips Healthcare for healthcare, Philips Lighting for lighting and Consumer Lifestyle for consumer products.
This company is an American medical technology provider. It is actually a wholly owned subsidiary of Hill Rom Holding Inc. and was formerly part of Hillenbrand Industries until the separation of that company from its medical equipment division.
is a manufacturer, designer and distributor of products and systems for respiratory care, acute care and sleep apnea treatment. The company is based in New Zealand and their products are marketed in nearly 120 countries worldwide. It is essentially an exporting company.
Although ResMed has not entered into many partnerships in recent years, the company's share price has benefited from the advantages of some strategic transactions. This was the case with the following example:
In 2020, the group signed a strategic agreement to complete the acquisition of Propeller Health, a digital therapeutics company that provides connected health solutions for people with chronic obstructive pulmonary disease and asthma. But Propeller will continue to operate as a stand-alone business from its Madison, Wisconsin and San Francisco offices, working with leading pharmaceutical partners and other healthcare organizations to deliver digital therapeutics and actionable information to people who use inhalers, helping them improve medication compliance, increase symptom-free days and reduce emergency room visits.
A portion of the ResMed Group's capital is currently owned by large private institutional investors including The Vanguard Group with 10.3%, Capital Research & Management with 6.73%, WCM Investment Management with 6.24%, Friess Associates with 4.81%, Principal Global Investors Australia with 4.38%, SSgA Funds Management Inc. with 4.25%, Fidelity Management & Research with 2.57%, BlackRock Fund Advisors with 2.13% and Geode Capital Management with 2.02%.
In order to anticipate future price variations of the ResMed share, it is preferable to carry out several types of analysis beforehand. We will concentrate here more particularly on the fundamental analysis which amounts to studying the external elements, publications or events being able to influence the price of this value and on the technical analysis which consists this time in a study of the stock exchange charts and the various historical movements of this price in order to detect the tendencies.
There are currently several ways to invest in US stocks like ResMed stock. You can buy this stock to add to your PEA or stock account portfolio or you can speculate on its price using derivatives such as CFDs or contracts for difference. These products allow you to trade on the rise or fall of this stock without having to hold it.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 77% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
